BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35241480)

  • 21. The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells.
    Kim SL; Kim EM; Cheong SJ; Lee CM; Kim DW; Jeong HJ; Lim ST; Sohn MH; Yim CY
    Nucl Med Biol; 2009 May; 36(4):427-33. PubMed ID: 19423011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [PET evaluation of glucose metabolism in cancer].
    Yasuda S; Fujii H; Takahashi W; Takagi S; Ide M; Shohtsu A
    Gan To Kagaku Ryoho; 1999 May; 26(6):756-61. PubMed ID: 10410143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
    Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
    Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT?
    Mirpour S; Meteesatien P; Khandani AH
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):71-7. PubMed ID: 22088805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Glucose Uptake in Normal and Cancer Cell Lines by Positron Emission Tomography.
    Maddalena F; Lettini G; Gallicchio R; Sisinni L; Simeon V; Nardelli A; Venetucci AA; Storto G; Landriscina M
    Mol Imaging; 2015; 14():490-8. PubMed ID: 26461458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.
    Kubota K
    Ann Nucl Med; 2001 Dec; 15(6):471-86. PubMed ID: 11831394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.
    Broecker-Preuss M; Becher-Boveleth N; Bockisch A; Dührsen U; Müller S
    J Transl Med; 2017 Jul; 15(1):158. PubMed ID: 28724379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro.
    Ogawa M; Nakamura S; Saito Y; Kosugi M; Magata Y
    J Nucl Med; 2012 Jan; 53(1):55-8. PubMed ID: 22128324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogene pathway activation in mammary tumors dictates FDG-PET uptake.
    Alvarez JV; Belka GK; Pan TC; Chen CC; Blankemeyer E; Alavi A; Karp JS; Chodosh LA
    Cancer Res; 2014 Dec; 74(24):7583-98. PubMed ID: 25239452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
    Kelly CJ; Hussien K; Muschel RJ
    Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond.
    Mankoff DA; Eary JF; Link JM; Muzi M; Rajendran JG; Spence AM; Krohn KA
    Clin Cancer Res; 2007 Jun; 13(12):3460-9. PubMed ID: 17575208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD147-mediated glucose metabolic regulation contributes to the predictive role of
    Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
    Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
    Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
    Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-FDG PET and PET/CT in fever of unknown origin.
    Meller J; Sahlmann CO; Scheel AK
    J Nucl Med; 2007 Jan; 48(1):35-45. PubMed ID: 17204697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors.
    Kaira K; Okumura T; Ohde Y; Takahashi T; Murakami H; Oriuchi N; Endo M; Kondo H; Nakajima T; Yamamoto N
    J Nucl Med; 2011 May; 52(5):705-11. PubMed ID: 21498541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer.
    Tohma T; Okazumi S; Makino H; Cho A; Mochiduki R; Shuto K; Kudo H; Matsubara K; Gunji H; Ochiai T
    Hepatogastroenterology; 2005; 52(62):486-90. PubMed ID: 15816463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG PET Hybrid Imaging.
    Becker J; Schwarzenböck SM; Krause BJ
    Recent Results Cancer Res; 2020; 216():625-667. PubMed ID: 32594401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
    Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
    J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between 18F-FDG accumulation and lactate dehydrogenase A expression in lung adenocarcinomas.
    Zhou X; Chen R; Xie W; Ni Y; Liu J; Huang G
    J Nucl Med; 2014 Nov; 55(11):1766-71. PubMed ID: 25342384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer.
    Takebayashi R; Izuishi K; Yamamoto Y; Kameyama R; Mori H; Masaki T; Suzuki Y
    J Exp Clin Cancer Res; 2013 May; 32(1):34. PubMed ID: 23718763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.